BCAB (STOCKS)
BioAtla, Inc. Common Stock
$4.575000
+0.115000 (+2.58%)
Prev close: $4.460000
Company Information
- Exchange
- XNAS
- Sector
- Health Technology
- Industry
- Biotechnology
- CEO
- Jay M. Short
- Asset Type
- stocks
- Website
- Visit
Fundamentals
- Market Cap
- $7.58M
- Employees
- 61
- P/E (TTM)
- -0.09
- P/B (TTM)
- -0.16
- Dividend Yield
- —
Technical Indicators
- SMA 10
- —
- SMA 20
- —
- SMA 50
- —
- EMA 9
- —
- EMA 21
- —
- RSI
- —
- MACD State
- —
Analyst Recommendations
3
Strong Buy
3
Buy
1
Hold
0
Sell
Recent News
No recent news found for this ticker.
Earnings Surprises
| Period | Actual | Estimate | Surprise | Surprise % |
|---|---|---|---|---|
|
Dec 2025 (Q4)
|
$-8.00 | $-12.24 | +4.2400 | +34.64% |
|
Sep 2025 (Q3)
|
$-13.50 | $-15.13 | +1.6302 | +10.77% |
|
Jun 2025 (Q2)
|
$-16.00 | $-17.21 | +1.2125 | +7.04% |
|
Mar 2025 (Q1)
|
$-13.00 | $-17.68 | +4.6802 | +26.47% |
Financial Statements
| Revenues | $2.00M |
| Benefits Costs and Expenses | $61.61M |
| Costs And Expenses | $61.31M |
| Operating Expenses | $61.31M |
| Research and Development | $43.57M |
| Other Operating Expenses | $17.73M |
| Operating Income/Loss | -$59.31M |
| Income/Loss From Continuing Operations After Tax | -$59.61M |
| Income/Loss From Continuing Operations Before Tax | -$59.61M |
| Income Tax Expense/Benefit | $0.00 |
| Income Tax Expense/Benefit, Deferred | $0.00 |
| Net Income/Loss | -$59.61M |
| Net Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Net Income/Loss Attributable To Parent | -$59.61M |
| Net Income/Loss Available To Common Stockholders, Basic | -$59.61M |
| Participating Securities, Distributed And Undistributed Earnings/Loss, Basic | $0.00 |
| Preferred Stock Dividends And Other Adjustments | $0.00 |
| Basic Earnings Per Share | -$1.01 |
| Diluted Earnings Per Share | -$1.01 |
| Basic Average Shares | 58,827,934 |
| Diluted Average Shares | 58,827,934 |
| Assets | $13.83M |
| Current Assets | $8.01M |
| Noncurrent Assets | $5.82M |
| Fixed Assets | $120.00K |
| Other Non-current Assets | $5.70M |
| Liabilities | $50.02M |
| Current Liabilities | $21.92M |
| Accounts Payable | $8.19M |
| Other Current Liabilities | $13.73M |
| Noncurrent Liabilities | $28.10M |
| Equity | $36.19M |
| Equity Attributable To Noncontrolling Interest | $72.38M |
| Equity Attributable To Parent | -$36.19M |
| Liabilities And Equity | $13.83M |
| Net Cash Flow From Operating Activities | -$48.20M |
| Net Cash Flow From Operating Activities, Continuing | -$48.20M |
| Net Cash Flow From Investing Activities | $41.93M |
| Net Cash Flow From Investing Activities, Continuing | $41.93M |
| Net Cash Flow From Financing Activities | $6.28M |
| Net Cash Flow From Financing Activities, Continuing | $6.28M |
| Net Cash Flow | $0.00 |
| Net Cash Flow, Continuing | $0.00 |
| Comprehensive Income/Loss | -$59.61M |
| Comprehensive Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Comprehensive Income/Loss Attributable To Parent | -$59.61M |
| Other Comprehensive Income/Loss | $0.00 |